However, nearly 30% of IBD patients do not have an initial clinical response to anti-TNF agents, and less than 50% of them could achieve mucosal healing eventually (Colombel et al., 2010; Roda et al., 2016). The gene discussed is TNF; the disease is inflammatory bowel disease.